Table 1.
Candidate repositioned drugs with anticancer effect in Japan in UMIN‐CTR
| Candidate drug | Effect as approved drug | Disease targeted by DR | Number of registrations | UMIN ID | Number of registrations (overseas)a |
|---|---|---|---|---|---|
| Aspirin | NSAID | CRC, FAP | 5 | 000031532, 000018736, 000018734, 000000698, 000000697 | 84 |
| Zoledronic acid | Osteoclastic inhibitor | BC, MPM, ATL, PrC, AML | 8 | 000008701, 000008093, 000007569, 000006736, 000003493, 000003261, 000002577, 000000796 | 62 |
| Nitroglycerin | Angina | NSCLC | 2 | 000001820, 000000813 | 7 |
| Menatetrenone | Hemostatic agent | HCC | 1 | 000001815 | 0 |
| Pipsissewa extract | Prostatic hyperplasia | Patients without PrC with high PSA | 1 | 000002126 | 0 |
| Candesartan cilexetil | Hypertension | HCC, PaC | 2 | 000002435, 000002152 | 0 |
| Metformin | Diabetes mellitus | Solid cancer, UC, PaC, LC | 7 | 000028405, 000020856, 000020681, 000020306, 000017694, 000004852, 000002210 | 163 |
| Branched‐chain amino acid | Hepatic encephalopathy | HCC | 1 | 000002330 | 0 |
| Celecoxib | NSAID (COX‐2 inhibitor) | HCC | 1 | 000002435 | 175 |
| Sodium valproate | Seizures | ESCC, PaC, BtC | 2 | 000010817, 000004525 | 63 |
| Atrial natriuretic polypeptide | Natriuretic peptide hormone | CRC,NSCLC, LC | 6 | 000025877, 000024302, 000019627, 000018851, 000018480, 000004880 | 0 |
| Irsogladine Maleate | Gastric mucosal protectant | NSCLC | 1 | 000005901 | 0 |
| Pioglitazone | Diabetes mellitus | HCC | 1 | 000007344 | 24 |
| Rifampicin | Antibiotic | HCC | 2 | 000007668, 000007667 | 29 |
| Mefenamic acid | NSAID | Head and neck cancer | 1 | 000007871 | 0 |
| Cilostazol | Antithrombotic agent | Head and neck cancer | 1 | 000007871 | 0 |
| Tranilast | Anti–allergy drug | Lymphatic tumor | 1 | 000008210 | 0 |
| Disulfiram | Alcoholism | HCC | 1 | 000008529 | 18 |
| Deferoxamine mesilate | Iron chelator | PaC | 1 | 000009054 | 0 |
| Sulfasalazine | Rheumatoid arthritis | NSCLC (non–SCC), GC | 2 | 000017854, 000010254 | 5 |
| Ribavirin | Antiviral agent | PrC | 1 | 000012521 | 21 |
| Azilsartan | Hypertension | PrC | 1 | 000012656 | 0 |
| Retinoic acid | Vitamin A | Neuroblastoma | 1 | 000013672 | 72 |
| Itraconazole | Antifungal medication | PaC, solid cancer | 3 | 000025398, 000018388, 000013951 | 49 |
| Propagermanium | Chronic hepatitis type B | PaC, BC, CRC, GC | 6 | 000027441, 000022494, 000022440, 000022129, 000017123, 000014689 | 0 |
| Mesalazine | Inflammatory bowel disease | FAP | 1 | 000018736 | 3 |
| Naftopidil | Prostatic hyperplasia | PrC | 1 | 000022862 | 0 |
| Cefadroxil | Bactericidal antibiotic | CML | 1 | 000027904 | 0 |
| Bezafibrate | Hyperlipidemia | NSCLC | 1 | 000029854 | 0 |
Abbreviations: AML, acute myeloid leukemia; ATL, adult T‐cell leukemia; BC, breast cancer; BtC, biliary tract cancer; CML, chronic myeloid leukemia; CRC, colorectal cancer; ESCC, esophageal squamous cell cancer; FAP, familial adenomatous polyposis; GC, gastric cancer; GyC, gynecologic cancer; HCC, hepatocellular cancer; LC, lung cancer; MPM, malignant pleural mesothelioma; NSAID, nonsteroidal anti–inflammatory drug; NSCLC, non–small cell lung cancer; PaC, pancreatic cancer; PrC, prostate cancer; UC, urological cancer.
a
The numbers are obtained using ClinicalTrials.gov.